ABL1 and amyotrophic lateral sclerosis: Imamura et al. [150] determined that Src/c-Abl could be an efficient target for ALS treatment, based on HTS conducted for 1416 compounds, using ALS survival of motor neurons generated from an ALS patient harbouring SOD1 mutations.